The FDA already had a mechanism for this purpose, as did 38 states. After the passing of this bill, Senator Ron Johnson, one of the bill's sponsors, took upon h

The FDA already had a mechanism for this purpose, as did 38 states. After the passing of this bill, Senator Ron Johnson, one of the bill's sponsors, took upon himself the privilege of explaining how it should be implemented to FDA Commissioner Scott Gottlieb (a Trump appointee), apparently because Gottlieb expressed excessive concern for patients' well-being. This raises the possibility that the bill's authors were coy about their intentions, perhaps to avoid them being scrutinized prior to its passage, and I hope the FDA will interpret it as written, and consistently with its broader responsibilities. https://arstechnica.com/science/2018/06/new-drug-access-law-intended-to-weaken-fda-according-to-lawmaker-behind-it/ https://arstechnica.com/science/2018/06/new-drug-access-law-...